Tacrolimus (Oral)
A calcineurin inhibitor. It is more potent than cyclosporine. Requires frequent blood level monitoring (Trough levels) to prevent toxicity.
Dosage by Body Weight
Pediatric dose: 0.1 mg/kg to 0.15 mg/kg per dose, twice daily. Target levels vary by transplant type.
- Body Weight
- 10-20 kg
- Dose
- 1 mg to 3 mg
- Frequency
- Twice daily
- Tracking Notes
- Take 12 hours apart at the same time every day.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| 10-20 kg | 1 mg to 3 mg | Twice daily | Take 12 hours apart at the same time every day. |
Formulation
Purpose
Primary immunosuppressant to prevent rejection after kidney, liver, or heart transplants.
Generic Name
Tacrolimus (FK506)Branded Drug Names
Tacrolimus (Oral) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
Safety Advice
Alcohol
CAUTIONTacrolimus (Oral): Alcohol can increase liver strain, stomach irritation, or immune-related complications. Avoid alcohol unless your specialist allows it.
Pregnancy
CAUTIONTacrolimus (Oral): Use in pregnancy only under specialist advice because immune, cancer, or transplant treatment requires careful risk assessment.
Breast Feeding
CAUTIONTacrolimus (Oral): Breastfeeding may not be recommended with some immunosuppressive or chemotherapy medicines. Follow specialist advice.
Driving
CAUTIONTacrolimus (Oral): May cause dizziness, fatigue, nausea, or weakness. Avoid driving if affected.
Liver
CAUTIONTacrolimus (Oral): Can affect liver function and usually requires regular blood tests. Use only with specialist monitoring.
Kidney
CAUTIONTacrolimus (Oral): Kidney function may need close monitoring, particularly with calcineurin inhibitors or high-risk regimens.